Beta-amyloid, oxidative stress and down syndrome

Current Alzheimer Research

Volumn 3, Issue 5, 2006, Pages 521-528

  Lott, Ira T ^a,b   Head, Elizabeth ^a   Doran, Eric ^a   Busciglio, Jorge ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

A ; Alzheimer disease; Amyloid; Down syndrome; DSRC1 stress inducible factor; Ets 2 transcription factor; Oxidative stress; SOD 1; Somatic DNA mutations

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; OLIGOMER; PROTEIN ETS 2; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DOWN SYNDROME; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW;

AGE FACTORS; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DOWN SYNDROME; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HUMANS; MODELS, BIOLOGICAL; MUTATION; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE;

EID: 33846081524     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506779025305     Document Type: Review

References (110)

1. CDC. Improved national prevalence estimates for 18 selected major birth defects - United States, 1999-2001; (2006).
2. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet 5(10):725-38 (2004).
3. Helguera P, Pelsman A, Pigino G, Wolvetang E, Head E, Busciglio J. ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. J Neurosci 25(9):2295-303 (2005).
4. Chang KT, Min KT. Drosophila melanogaster homolog of Down syndrome critical region 1 is critical for mitochondrial function. Nat Neurosci 8(11):1577-85 (2005).
5. Mann DM, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci89(2-3):169-79 (1989).
6. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 150(2):296-304 (1998).
7. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol17(3):278-82 (1985).
8. Lott IT, Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging 26(3):383-9 (2005).
9. Tyrrell J, Cosgrave M, McCarron M, McPherson J, Calvert J, Kelly A, et al. Dementia in people with Down's syndrome. Int J Geriatr Psychiatry 16(12):1168-74 (2001).
10. Schupf N, Sergievsky GH. Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry 180:405-10 (2002).
11. Mrak RE, Griffin WS. Trisomy 21 and the brain. J Neuropathol Exp Neurol 63(7):679-85 (2004).
12. Moreira PI, Honda K, Zhu X, Nunomura A, Casadesus G, Smith MA, et al. Brain and brawn: parallels in oxidative strength. Neurology 66(2 Suppl 1):S97-101 (2006).
13. Nelson LD, Orme D, Osann K, Lott IT. Neurological changes and emotional functioning in adults with Down Syndrome. J Intellect Disabil Res 45(Pt 5):450-6 (2001).
14. Azizeh BY, Head E, Ibrahim MA, Torp R, Tenner AJ, Kim RC, et al. Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs. Exp Neurol 163(1):111-22 (2000).
15. Haier RJ, Alkire MT, White NS, Uncapher MR, Head E, Lott IT, et al. Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia. Neurology 61(12):1673-9 (2003).
16. Head E, Lott IT, Hof PR, Bouras C, Su JH, Kim R, et al. Parallel compensatory and pathological events associated with tau pathology in middle aged individuals with Down syndrome. J Neuropathol Exp Neurol 62(9):917-26 (2003).
17. Lott IT, Osann K, Doran E, Nelson L. Down syndrome and Alzheimer disease: response to donepezil. Arch Neurol 59(7):1133-6 (2002).
18. Prasher VP, Adams C, Holder R. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study. Int J Geriatr Psychiatry 18(6):549-51 (2003).
19. Heller JH, Spiridigliozzi GA, Sullivan JA, Doraiswamy PM, Krishnan RR, Kishnani PS. Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. Am J Med Genet A 116(2):111-6 (2003).
20. Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D. Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard 108(6):367-72 (2003).
21. Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C. Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis 8(5):792-806 (2001).
22. Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Amyloid Beta: the alternate hypothesis. Curr Alzheimer Res 3(1):75-80 (2006).
23. Garcez ME, Peres W, Salvador M. Oxidative stress and hematologic and biochemical parameters in individuals with Down syndrome. Mayo Clin Proc 80(12):1607-11 (2005).
24. Wirths O, Multhaup G, Bayer TA. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide - the first step of a fatal cascade. J Neurochem 91(3):513-20 (2004).
25. Oyama F, Cairns NJ, Shimada H, Oyama R, Titani K, Ihara Y. Down's syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination. J Neurochem 62(3):1062-6 (1994).
26. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38(1):24-6 (2006).
27. Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Review in Clin. Neurosci. 33:403-408 (1993).
28. Lai F, and Williams, M.D. A prospective study of Alzheimer Disease in Down Syndrome. Archives of Neurology 46:849-853 (1989).
29. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 43(3):380-3 (1998).
30. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu. Rev. Neurosci. 17:489-517 (1994).
31. Nunan J, Small, D.H. Regulation of APP cleavage by α-, β- and γ-secretases. FEBS Lett 483:6-10 (2000).
32. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440):735-41 (1999).
33. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273(43):27765-7 (1998).
34. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96(7):3922-7(1999).
35. Acquati F, Accarino M, Nucci C, Fumagalli P, Jovine L, Ottolenghi S, et al. The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region. FEBS Lett 468(1):59-64 (2000).
36. Barbiero L, Benussi L, Ghidoni R, Alberici A, Russo C, Schettini G, et al. BACE-2 is overexpressed in Down's syndrome. Exp Neurol 2003;182:335-345.
37. Motonaga K, Itoh, M, Becker LE, Goto Y, Takashima S. Elevated expression of beta-site amyloid precursor protein cleaving enzyme 2 in brains of patients with Down syndrome. Neurosci Lett 326:64-66 (2002).
38. Lee EB, Zhang B, Liu K, Greenbaum EA, Doms RW, Trojanowski JQ, et al. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J Cell Biol 168(2):291-302 (2005).
39. Marcinkiewicz M, Seidah NG. Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. J Neurochem 75(5):2133-43 (2000).
40. Bennett BD, Babu-Khan S, Loeloff R, Louis JC, Curran E, Citron M, et al. Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 275(27):20647-51 (2000).
41. Dingwall C. Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease. J Clin Invest 108(9):1243-6 (2001).
42. Koo EH. The beta-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog? Traffic 3(11):763-70 (2002).
43. Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, and Price DL. Precursor of amyloid protein in Alzheimer's diase undergoes fast anterograde axonal transport. Proc Natl Acad Sci USA 87:1561-1565 (1990).
44. Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125(4):489-92 (2001).
45. Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, et al. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging 25(10):1263-72 (2004).
46. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 157:277-286 (2000).
47. Grbovic OM, Matthews PM, Jiang Y, Schmidt SD, Dinakar R, Summers-Terio NB, et al. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular β-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Aβ production. J Biol Chem 278(33):31261-31268 (2003).
48. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, et al. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22(5):1858-1867 (2002).
49. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-β oligomers: their production, toxicity and therapeutic inhibition. Biochemical Society Transactions 30(4):552-557 (2002).
50. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusable, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453 (1998).
51. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489 (2003).
52. Sadowski M, Wisniewski HM, Tarnawski M, Kozlowski PB, Lach B, Wegiel J. Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss caused by neurofibrillary pathology. Acta Neuropathol (Berl) 97(2):156-64 (1999).
53. Lott IT, Head E. Down syndrome and Alzheimer's disease: A link between development and aging. Ment Retard Dev Disabil Res Rev 7(3):172-8 (2001).
54. Glabe C. Does Alzheimer disease tilt the scales of amyloid degradation versus accumulation? Nature Medicine 6(2):133-134 (2000).
55. Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269(18):13623-8 (1994).
56. Frederikse PH, Garland D, Zigler JS, Jr., Piatigorsky J. Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J Biol Chem 271(17):10169-74 (1996).
57. Gasparini L, Racchi M, Benussi L, Curti D, Binetti G, Bianchetti A, et al. Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci Lett 231(2):113-7(1997).
58. Misonou H, Morishima-Kawashima M, Ihara Y. Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry 39(23):6951-9 (2000).
59. Song ES, Juliano MA, Juliano L, Hersh LB. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. J Biol Chem 278(50):49789-94 (2003).
60. Song ES, Mukherjee A, Juliano MA, Pyrek JS, Goodman JP, Jr., Juliano L, et al. Analysis of the subsite specificity of rat insulysin using fluorogenic peptide substrates. J Biol Chem 276(2):1152-5 (2001).
61. Li C, Hersh LB. Neprilysin: assay methods, purification, and characterization. Methods Enzymol 248:253-63 (1995).
62. Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 38(35):11570-6 (1999).
63. Kingston IB, Castro MJ, Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat Med 1(2):138-42 (1995).
64. Wang D-S, Iwata N, Hama E, Saido TC, Dickson DW. Oxidized neprilysin in aging and Alzheimer's disease brains. Biochemical and biophysical research communications 310:236-241 (2003).
65. Kedziora J, Bartosz G. Down's syndrome: a pathology involving the lack of balance of reactive oxygen species. Free Radic Biol Med 4(5):317-30 (1988).
66. Busciglio J, Andersen JK, Schipper HM, Gilad GM, McCarty R, Marzatico F, et al. Stress, aging, and neurodegenerative disorders. Molecular mechanisms. Ann N Y Acad Sci 851:429-43(1998).
67. Reynolds GP, Cutts AJ. Free radical damage in Down's syndrome brain. Biochem Soc Trans 21(2):221S (1993).
68. Brooksbank BW, Martinez M, Balazs R. Altered composition of polyunsaturated fatty acyl groups in phosphoglycerides of Down's syndrome fetal brain. J Neurochem 44(3):869-74 (1985).
69. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378(6559):776-9 (1995).
70. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36(5):747-51 (1994).
71. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, et al. Oxidative damage in Alzheimer's. Nature 382(6587):120-1(1996).
72. Sinet PM. Metabolism of oxygen derivatives in down's syndrome. Ann N Y Acad Sci 396:83-94 (1982).
73. de Haan JB, Wolvetang EJ, Cristiano F, Iannello R, Bladier C, Kelner MJ, et al. Reactive oxygen species and their contribution to pathology in Down syndrome. Adv Pharmacol 38:379-402 (1997).
74. Korenberg JR, Kawashima H, Pulst SM, Allen L, Magenis E, Epstein CJ. Down syndrome: toward a molecular definition of the phenotype. Am J Med Genet Suppl 7:91-7(1990).
75. Badwey JA, Karnovsky ML. Active oxygen species and the functions of phagocytic leukocytes. Annu Rev Biochem 49:695-726 (1980).
76. Elroy-Stein O, Bernstein Y, Groner Y. Overproduction of human Cu/Zn-superoxide dismutase in transfected cells: extenuation of paraquat-mediated cytotoxicity and enhancement of lipid peroxidation. EMBO J 5(3):615-22 (1986).
77. Norris KH, Hornsby PJ. Cytotoxic effects of expression of human superoxide dismutase in bovine adrenocortical cells. Mutat Res 237(2):95-106 (1990).
78. Yarom R, Sherman Y, Sagher U, Peled IJ, Wexler MR, Gorodetsky R. Elevated concentrations of elements and abnormalities of neuromuscular junctions in tongue muscles of Down's syndrome. J Neurol Sci 79(3):315-26 (1987).
79. Capone G, Kim P, Jovanovich S, Payne L, Freund L, Welch K, et al. Evidence for increased mitochondrial superoxide production in Down syndrome. Life Sci 70(24):2885-95 (2002).
80. Gerli G, Zenoni L, Locatelli GF, Mongiat R, Piattoni F, Orsini GB, et al. Erythrocyte antioxidant system in Down syndrome. Am J Med Genet Suppl 7:272-3 (1990).
81. Brooksbank BW, Balazs R. Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain. Brain Res 318(1):37-44 (1984).
82. de Haan JB, Cristiano F, Iannello R, Bladier C, Kelner MJ, Kola I. Elevation in the ratio of Cu/Zn-superoxide dismutase to glutathione peroxidase activity induces features of cellular senescence and this effect is mediated by hydrogen peroxide. Hum Mol Genet 5(2):283-92 (1996).
83. Bar-Peled O, Korkotian E, Segal M, Groner Y. Constitutive overexpression of Cu/Zn superoxide dismutase exacerbates kainic acidinduced apoptosis of transgenic-Cu/Zn superoxide dismutase neurons. Proc Natl Acad Sci USA 93(16):8530-5 (1996).
84. Delacourte A, Defossez A, Ceballos I, Nicole A, Sinet PM. Preferential localization of copper zinc superoxide dismutase in the vulnerable cortical neurons in Alzheimer's diasease. Neurosci Lett 92:247-253(1998).
85. Furuta A, Price DL, Pardo CA, Troncoso JC, Xu ZS, Taniguchi N, et al. Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol 146(2):357-67(1995).
86. Okado-Matsumoto A, Fridovich I. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J Biol Chem 276(42):38388-93 (2001).
87. Macleod K, Leprince D, Stehelin D. The ets gene family. Trends Biochem Sci 17(7):251-6 (1992).
88. Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. Eur J Biochem 211(1-2):7-18 (1993).
89. Bhat NK, Fisher RJ, Fujiwara S, Ascione R, Papas TS. Temporal and tissue-specific expression of mouse ets genes. Proc Natl Acad Sci USA 84(10):3161-5 (1987).
90. Kola I, Brookes S, Green AR, Garber R, Tymms M, Papas TS, et al. The Ets1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation. Proc Natl Acad Sci USA 90(16):7588-92 (1993).
91. Wolvetang EJ, Wilson TJ, Sanij E, Busciglio J, Hatzistavrou T, Seth A, et al. ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway. Hum Mol Genet 12(3):247-55 (2003).
92. Wolvetang EJ, Bradfield OM, Hatzistavrou T, Crack PJ, Busciglio J, Kola I, et al. Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis. Neurobiol Dis 14(3):349-56 (2003).
93. Schupf N, Patel B, Silverman W, Zigman WB, Zhong N, Tycko B, et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 301(3):199-203 (2001).
94. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2(1):93-5 (1996).
95. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3(1):16-32 (1996).
96. Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, et al. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9(2):88-102 (2002).
97. Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33(5):677-88 (2002).
98. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77(6):817-27 (1994).
99. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 91(8):3270-4 (1994).
100. Puglielli L, Friedlich AL, Setchell KD, Nagano S, Opazo C, Cherny RA, et al. Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J Clin Invest 115(9):2556-63 (2005).
101. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's diseaserelated cognitive deficits in transgenic mice. Neuron 45(5):675-88 (2005).
102. Crawford DR, Leahy KP, Abramova N, Lan L, Wang Y, Davies KJ. Hamster adapt78 mRNA is a Down syndrome critical region homologue that is inducible by oxidative stress. Arch Biochem Biophys 342(1):6-12 (1997).
103. Lin HY, Michtalik HJ, Zhang S, Andersen TT, Van Riper DA, Davies KK, et al. Oxidative and calcium stress regulate DSCR1 (Adapt78/MCIP1) protein. Free Radic Biol Med 35(5):528-39 (2003).
104. Ermak G, Cheadle C, Becker KG, Harris CD, Davies KJ. DSCR1(Adapt78) modulates expression of SOD1. FASEB J 18(1):62-9 (2004).
105. Ermak G, Morgan TE, Davies KJ. Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease. J Biol Chem 276(42):38787-94 (2001).
106. Wallace DC. Mitochondrial diseases in man and mouse. Science 283(5407):1482-8 (1999).
107. Zeviani M, Carelli V. Mitochondrial disorders. Curr Opin Neurol 16(5):585-94 (2003).
108. Larsen NB, Rasmussen M, Rasmussen LJ. Nuclear and mitochondrial DNA repair: similar pathways? Mitochondrion 5(2):89-108 (2005).
109. Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA 101(29):10726-31 (2004).
110. Coskun PE, Derbeneva OA, Head E, Lott IT, Wallace DC. mtDNA control region mutations in the brains of patients with Down's syndrome with dementia. In: Society for Neuroscience; 2005; Washington, DC; 2005.